The societal impact of this project is profound, with the potential to revolutionize cancer detection and treatment. By using advanced sequencing technologies, early cancer detection might be possible through a blood test that detects signs of cancer, including tumor cells and cell free DNA originating from cancer cells. This method is known as a liquid biopsy. This approach can be used at diagnosis when a tissue biopsy is not informative, at relapse after treatment prior to repeat tissue biopsy, and can enable minimal residual disease detection. This early detection would not only improve patient outcomes but also reduce the burden on healthcare systems by minimizing the need for invasive procedures and costly late-stage treatments. Furthermore, the ability to tailor treatments to individual genetic profiles through personalized medicine could increase treatment efficacy and reduce unnecessary side effects. Additionally, liquid biopsies could increase accessibility to cancer diagnostics, especially in underserved or remote regions, where traditional biopsy methods are not feasible. While these advancements promise to improve healthcare efficiency and patient quality of life. In summary, this project has the potential to change the landscape of cancer diagnosis and treatment by offering a more effective, less invasive, and cost-efficient approach, while also fostering innovation in personalized medicine and genomic research. The societal benefits extend beyond individual patient care, contributing to a more accessible and efficient healthcare system globally.